Fortified Phosphorus‑lowering Treatment Through Administration of Lanthanum Protects Against Vascular Calcification Via Regulation of FGF23 in Chronic Kidney Disease

Overview

Journal Int J Mol Med

Specialty Genetics

Date 2020 Sep 9

PMID 32901861

Citations 1

Authors

Jie Jiang

Yi Li

Dongwen Zheng

Zhen Wang

Hongmei Zhou

Guohui Liu

Affiliations

Soon will be listed here.

Abstract

Phosphorus reduction can prevent against vascular calcification (VC) in chronic kidney disease (CKD), but the mechanisms underlying its actions remain unclear. The aim of the present study was to determine the effect of a fortified phosphorus‑lowing treatment on VC in CKD. Serum levels of creatinine, blood urea nitrogen (BUN), fibroblast growth factor 23 (FGF23), calcium and phosphorus, and the plasma levels of parathyroid hormone (PTH) were determined in an animal model of CKD treated with or without lanthanum. Haematoxylin and eosin (H&E) staining was performed to examine the structure of kidney tissues. Western blot analysis was performed to compare the levels of total‑ (t‑) extracellular signal‑related kinase (ERK) and phospho‑ (p‑)ERK among the different experimental groups to investigate the effect of FGF23 on p‑ERK expression. In the animal model, administration of adenine increased the serum levels of creatinine, BUN, FGF23 and phosphorus but decreased the serum levels of calcium. In addition, adenine treatment increased the plasma levels of PTH. H&E staining showed that lanthanum treatment did not alter the severity of renal cortex injury. Furthermore, the levels of t‑ERK levels did not notably differ between the Adenine‑free, Adenine‑vehicle and Adenine‑lanthanum groups, whereas the levels of p‑ERK and aortic calcium in the Adenine‑vehicle group were significantly upregulated. In addition, ectopic overexpression of FGF23 increased the levels of p‑ERK, Msx2 and Osx in a dose‑dependent manner. Furthermore, a total of 48 patients were enrolled in the present study. In the fortified group, the serum levels of FGF23, phosphorus and PTH were significantly reduced, whereas the serum levels of calcium were significantly increased, indicating an enhanced preventative effect in the fortified group. The results of the present study suggest that FGF23 may be used as a therapeutic target in the management and prevention of VC in CKD.

Citing Articles

Bibliometric and Visual Analysis of Vascular Calcification Research.

Dong Q, Liang Q, Chen Y, Li J, Lu L, Huang X Front Pharmacol. 2021; 12:690392.

PMID: 34335257 PMC: 8319769. DOI: 10.3389/fphar.2021.690392.

References

Goetz R, Mohammadi M . Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol. 2013; 14(3):166-80. PMC: 3695728. DOI: 10.1038/nrm3528. View

Yamazaki M, Ozono K, Okada T, Tachikawa K, Kondou H, Ohata Y . Both FGF23 and extracellular phosphate activate Raf/MEK/ERK pathway via FGF receptors in HEK293 cells. J Cell Biochem. 2010; 111(5):1210-21. DOI: 10.1002/jcb.22842. View

Jean G, Bresson E, Terrat J, Vanel T, Hurot J, Lorriaux C . Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant. 2008; 24(3):948-55. DOI: 10.1093/ndt/gfn571. View

Ben-Dov I, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-O M, Mohammadi M . The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007; 117(12):4003-8. PMC: 2066196. DOI: 10.1172/JCI32409. View

Ikushima M, Rakugi H, Ishikawa K, Maekawa Y, Yamamoto K, Ohta J . Anti-apoptotic and anti-senescence effects of Klotho on vascular endothelial cells. Biochem Biophys Res Commun. 2005; 339(3):827-32. DOI: 10.1016/j.bbrc.2005.11.094. View

Goodman W, Goldin J, Kuizon B, Yoon C, Gales B, Sider D . Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342(20):1478-83. DOI: 10.1056/NEJM200005183422003. View

Gutierrez O, Mannstadt M, Isakova T, Rauh-Hain J, Tamez H, Shah A . Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359(6):584-92. PMC: 2890264. DOI: 10.1056/NEJMoa0706130. View

Craver L, Marco M, Martinez I, Rue M, Borras M, Martin M . Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007; 22(4):1171-6. DOI: 10.1093/ndt/gfl718. View

. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-4. DOI: 10.1001/jama.2013.281053. View

10.

Shima W, Ali A, Subramani T, Mohamed Alitheen N, Hamid M, Samsudin A . Rapid growth and osteogenic differentiation of mesenchymal stem cells isolated from human bone marrow. Exp Ther Med. 2015; 9(6):2202-2206. PMC: 4473366. DOI: 10.3892/etm.2015.2381. View

11.

Xu L, Peng H, Wu D, Hu K, Goldring M, Olsen B . Activation of the discoidin domain receptor 2 induces expression of matrix metalloproteinase 13 associated with osteoarthritis in mice. J Biol Chem. 2004; 280(1):548-55. DOI: 10.1074/jbc.M411036200. View

12.

Lannuzel A, Barnier J, Hery C, Huynh V, Guibert B, Gray F . Human immunodeficiency virus type 1 and its coat protein gp120 induce apoptosis and activate JNK and ERK mitogen-activated protein kinases in human neurons. Ann Neurol. 1997; 42(6):847-56. DOI: 10.1002/ana.410420605. View

13.

Quarles L . Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008; 118(12):3820-8. PMC: 2586800. DOI: 10.1172/JCI36479. View

14.

Kohl L, Shroff G, Herzog C . Understanding risks associated with chronic kidney disease: translating observational data to patient care. Clin Chem. 2013; 59(6):876-9. DOI: 10.1373/clinchem.2012.201012. View

15.

Beckman M, Tadikonda P, Werner E, Prahl J, Yamada S, DeLuca H . Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry. 1996; 35(25):8465-72. DOI: 10.1021/bi960658i. View

16.

Wallin R, Wajih N, Greenwood G, Sane D . Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev. 2001; 21(4):274-301. DOI: 10.1002/med.1010. View

17.

Fukumoto S, Yamashita T . FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23. Bone. 2007; 40(5):1190-5. DOI: 10.1016/j.bone.2006.12.062. View

18.

You H, Yang H, Zhu Q, Li M, Xue J, Gu Y . Advanced oxidation protein products induce vascular calcification by promoting osteoblastic trans-differentiation of smooth muscle cells via oxidative stress and ERK pathway. Ren Fail. 2009; 31(4):313-9. DOI: 10.1080/08860220902875182. View

19.

Lim K, Lu T, Molostvov G, Lee C, Lam F, Zehnder D . Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation. 2012; 125(18):2243-55. DOI: 10.1161/CIRCULATIONAHA.111.053405. View

20.

Eliopoulos A, Wang C, Dumitru C, Tsichlis P . Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J. 2003; 22(15):3855-64. PMC: 169059. DOI: 10.1093/emboj/cdg386. View